Loading patent…
AssigneeCentre for Chinese Herbal Medicine Drug Development Limited
InventorsZhaoxiang BIAN, Lin ZHU, Ka Wing CHENG, Hor Yue TAN, Jingchun SHI, Chengyuan Lin, Chunhua HUANG
Estimating the term…
The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.
A pharmaceutical composition comprises 40-70 wt. % berberine, 10-40 wt. % militarine, 10-25 wt. % liquiritin, 5-10 wt. % curcumin, and 0.01-1 wt. % atractylenolide III being characterized by molecular docking with an ulcerative colitis (UC)-modulating target selected from the group consisting of MAOA, MAPK14, AHR, PTGS2, PLA2G1B, ALOX5, and a combination thereof.
A method of treating or alleviating ulcerative colitis (UC) in a subject in need thereof, comprises administering a therapeutically effective amount of a composition consisting of berberine, militarine, liquiritin, curcumin and atractylenolide III being characterized by molecular docking with the UC-modulating targets consisting of MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5 to the subject.
Dependencies are inferred from the claim text.